"2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see this as an important stepping stone. In the Annual and Sustainability Report, we outline how the strong growth we delivered throughout 2018 is fuelling our vision of becoming global leaders in providing innovative treatments that transform life for people with rare diseases".
Because we care, we need to act
Sobi 2018 Annual and Sustainability Report - now published
Sobi Capital Markets Day - 14 May
An opportunity for institutional investors, analysts and media to learn more about Sobi, our therapeutic areas and future growth strategy as well our financial performance.
Annual General Meeting 2019
The Annual General Meeting (“AGM”) in Swedish Orphan Biovitrum AB (publ) will be held on Thursday, May 9 at 3.00 p.m. at Grand Hôtel, S. Blasieholmshamnen 8, Stockholm, Sweden.
